greeksoup/ stock research
Stock research / United States / Funds / Sands Capital Alternatives, LLC

Sands Capital Alternatives, LLC

CIK 1846444 · latest 13F filed 13 August 2026 · Read the filing on EDGAR

Sands Capital Alternatives, LLC reported 24 US-listed holdings worth $613.5 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Alamar Biosciences Inc. (18.7%), Nu Holdings Ltd. (15.4%) and Klaviyo Inc. (9.7%). Against the quarter before, it opened 3 positions, added to 10, trimmed 2 and sold out of 0.

Filed before as Sands Capital Ventures, LLC.

Reported holdings$613.5M+45.7% on Q1 2026
Positions24+3 on Q1 2026
The largest ten80.8%of its reported holdings
Latest 13FQ2 2026filed 13 August 2026
Where the money is
OpenedAdded toHeldTrimmed
ALMR18.7%NU15.4%KVYO9.7%BBNX9.5%SGP9.1%IKT4.3%DASH3.8%CPNG3.8%DDOG3.4%BIOA3.1%TXG3.0%IOT2.7%ODTX2.7%TOST1.7%10 more9.1%

The 14 largest of its 24 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $355.8 million in 20 positions$356MQ3 24Q4 2024: $459.7 million in 21 positions$460MQ4 24Q1 2025: $408.9 million in 20 positions$409MQ1 25Q2 2025: $507.8 million in 19 positions$508MQ2 25Q3 2025: $456.4 million in 20 positions$456MQ3 25Q4 2025: $518.5 million in 20 positions$518MQ4 25Q1 2026: $421.2 million in 21 positions$421MQ1 26Q2 2026: $613.5 million in 24 positions$614MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned -12.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
90105120135Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings -12.1%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 3Added 10Held 9Trimmed 2
Opened: 3Added: 10Held: 9Trimmed: 2

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 3

  1. Alamar Biosciences Inc. ALMR$114.6 million
  2. Odyssey Therapeutics, Inc. ODTX$16.4 million
  3. Cerebras Systems Inc. Com Class A CBRS$7.3 million

Added to 10

  1. Nu Holdings Ltd. NU+557,183 shares · +9%
  2. Coupang Inc. Class A CPNG+317,223 shares · +31%
  3. Klaviyo Inc. KVYO+278,468 shares · +8%
  4. DoorDash, Inc. DASH+16,331 shares · +15%
  5. Toast, Inc. TOST+63,232 shares · +21%
  6. Servicetitan TTAN+18,689 shares · +21%
  7. Snowflake Inc. SNOW+4,245 shares · +21%
  8. monday.com Ltd. MNDY+14,114 shares · +21%

and 2 more in the table below

Trimmed 2

  1. Samsara Inc. IOT-44,629 shares · -8%
  2. Datadog, Inc. DDOG-4,942 shares · -6%

What it holds

CompanySharesValueOf its bookChange in shares
Alamar Biosciences Inc. ALMR4.2M$114.6 million18.68%new
Nu Holdings Ltd. NU7.1M$94.8 million15.45%+557.2K
Klaviyo Inc. KVYO3.9M$59.3 million9.67%+278.5K
Beta Bionics Inc BBNX3.7M$58.1 million9.47%no change
Spyglass Pharma Inc. SGP2.5M$55.7 million9.07%no change
Inhibikase Therapeutics Inc. IKT13.0M$26.4 million4.31%no change
DoorDash, Inc. DASH127.6K$23.5 million3.84%+16.3K
Coupang Inc. Class A CPNG1.3M$23.1 million3.76%+317.2K
Datadog, Inc. DDOG80.9K$21.1 million3.43%-4.9K
Bioage Labs Inc. BIOA786.4K$19.3 million3.14%no change
10X Genomics Inc. TXG481.8K$18.5 million3.01%no change
Samsara Inc. IOT515.7K$16.7 million2.73%-44.6K
Odyssey Therapeutics, Inc. ODTX875.0K$16.4 million2.67%new
Toast, Inc. TOST364.9K$10.2 million1.65%+63.2K
Acumen Pharmaceuticals Inc. ABOS3.7M$9.9 million1.62%no change
Servicetitan TTAN108.5K$7.7 million1.25%+18.7K
Cerebras Systems Inc. Com Class A CBRS32.8K$7.3 million1.18%new
Snowflake Inc. SNOW24.5K$6.2 million1.02%+4.2K
monday.com Ltd. MNDY82.0K$5.9 million0.97%+14.1K
Tarsus Pharmaceuticals Inc. TARS85.0K$5.3 million0.87%no change
Taysha Gene Therapies Inc. TSHA724.9K$4.9 million0.80%no change
Candel Therapeutics Inc. CADL405.8K$4.2 million0.68%no change
Acrivon Therapeutics Inc. ACRV2.3M$4.1 million0.66%+166.7K
Figma Inc. FIG22.2K$400,9650.07%+3.9K
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before.